Enhanced sensitivity to anti-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2273-2280

  Wani, Manzoor A ^a   Zhu, Qianzheng ^a   El Mahdy, Mohammed ^a   Venkatachalam, Sundaresan ^a,c   Wani, Altaf A ^a,b,d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER; CELL CYCLE; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; APOPTOSIS; BENZOPYRENES; CARCINOGENS; CELL LINE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DNA, SINGLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GENES, P53; GENOME, HUMAN; HUMANS; MUTATION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0034655114     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., and Epstein, C. B. The spectrum of mutations at the p53 locus. Ann. NY Acad. Sci., 768: 111-128, 1995.
2. Greenblatt, M. S., and Harris, C. C. Molecular genetics of lung cancer. Cancer Surv., 25: 293-313, 1995.
3. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
4. Cullinane, C., Mazur, S. J., Essigmann, J. M., Phillips, D. R., and Bohr, V. A. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry, 38: 6204-6212, 1999.
5. Yoon, J. H., Swiderski, P. M., Kaplan, B. E., Takao, M., Yasui. A., Shen, B. H., and Pfeifer, G. P. Processing of UV damage in vitro by FEN-1 proteins as part of an alternative DNA excision repair pathway. Biochemistry, 38: 4809-4817, 1999.
6. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. M., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., and Tainsky, M. A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
7. Price, B. D., and Park, S. J. DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res., 54: 896-899, 1994.
8. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
9. Fritche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging proteins. Oncogene, 8: 307-318, 1993.
10. Olive, P. L. DNA damage and repair in individual cells: applications of the comet assay in radiobiology. Int. J. Radiol. Biol., 75: 395-405, 1999.
11. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
12. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
13. Venkatachalam, S., Denissenko, M. F., Alvi, N., and Wani, A. A. Rapid activation of apoptosis in human promyelocytic leukemia cells by (±)-anti-benzo[a]pyrene-diol epoxide induced DNA damage. Biochem. Biophys. Res. Commun., 197: 722-729, 1993.
14. 2/M cell cycle checkpoint. Proc. Natl. Acad. Sci. USA, 96: 3706-3711, 1999.
15. Wang, X. W., Forrester, K., Yen, H., Feitelson, M. A., Gu, J-R., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA. 91: 2230-2234, 1994.
16. Ford, J. M., and Hanawalt, P. C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc. Natl. Acad. Sci. USA, 92: 8876-8880, 1995.
17. Wani, M. A., Zhu, Q. Z., El-mahdy, M., and Wani, A. A. Influence of p53 tumor suppressor protein on bias of DNA repair and apoptotic response in human cells. Carcinogenesis (Lond.), 20: 765-772, 1999.
18. Donehower, L. A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol., 7: 269-278, 1996.
19. Hanawalt, P. C. Genomic instability: environmental invasion and the enemies within. Mutat. Res., 400: 117-125, 1998.
20. Ford, J. M., and Hanawalt, P. C. Role of DNA excision repair gene defects in the etiology of cancer. Curr. Top. Microbiol. Immunol., 221: 47-70, 1997.
21. Sancar, A., and Sancar, G. B. DNA repair enzymes. Annu. Rev. Biochem., 57: 29-67, 1988.
22. Petit, C., and Sancar, A. Nucleotide excision repair: From E. coli to man. Biochimie, 81: 15-25, 1999.
23. Sancar, A. Excision repair in mammalian cells. J. Biol. Chem., 270: 15915-15918, 1995.
24. Phillips, D. H. Fifty years of benzo[a]pyrene. Nature (Lond.), 303: 468-472, 1983.
25. Denissenko, M. F., Cahill, J., Koudriakova, T. B., Gerber, N., and Pfeifer, G. P. Quantitation and mapping of aflatoxin B1-induced DNA damage in genomic DNA using aflatoxin B1-8,9-epoxide and microsomal activation systems. Mutat. Res., 425: 205-211, 1999.
26. Osborne, M. R., Jacobs, S., Harvey, R. G., and Brookes, P. Minor products from the reaction of (+) and (-) benzo[a]pyrene-anti-diolepoxide with DNA. Carcinogenesis (Lond.), 2: 553-558, 1981.
27. MacLeod, M. C. Interaction of bulky chemical carcinogens with DNA in chromatin. Carcinogenesis (Lond.), 16: 2009-2014, 1995.
28. MacLeod, M. C., Daylong, A., Adair, G., and Humphrey, R. M. Differences in the rate of DNA adduct removal and the efficiency of mutagenesis for two benzo-[a]pyrene diol epoxides in CHO cells. Mutat. Res., 1991.
29. Harris, C. C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res., 51: 5023s-5044s, 1991.
30. Conney, A. H., Chang, R. L., Jerina, D. M., and Wei, S-J. C. Studies on the metabolism of benzo[a]pyrene and dose-dependent differences in the mutagenic profile of its ultimate carcinogenic metabolite. Drug Metab. Rev., 26: 125-163, 1994,
31. Venkatachalam, S., Denissenko, M. F., and Wani, A. A. DNA repair in human cells: quantitative assessment of bulky anti-BPDE DNA adducts by non-competitive immunoassays. Carcinogenesis (Lond.). 16: 2029-2036, 1995.
32. Kem, S., Kinzler, K., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science (Washington DC), 252: 1708-1711, 1991.
33. Liu, P. K., Kraus, E., Wu, T. A., Strong, L. C., and Tainsky, M. A. Analysis of genomic instability in Li-Fraumeni fibroblasts with germ-line p53 mutations. Oncogene, 12: 2267-2278, 1996.
34. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
35. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofzinger, T. H., Currens, M. J., Seniff, and Boyd, M. R. Evaluation of soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
36. Venkatachalam, S., Denissenko, M., and Wani, A. A. Modulation of (+/-)-anti-BPDE mediated p53 accumulation by inhibitors of protein kinase C and poly(ADP-ribose) polymerase. Oncogene, 14: 801-809, 1997.
37. Venkatachalam, S., and Wani, A. A. Differential recognition of stereochemically defined base adducts by antibodies against anti-benzo[a]pyrene diol epoxide modified DNA. Carcinogenesis (Lond.), 15: 565-572, 1994.
38. Venkatachalam, S., Denissenko, M. F., and Wani, A. A. DNA repair in human cells: quantitative assessment of bulky anti-BPDE DNA adducts by non-competitive immunoassays. Carcinogenesis (Lond.), 16: 2029-2036, 1995.
39. Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., and Cline, M. J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA, 84: 7716-7719, 1987.
40. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1982.
41. 32-labeled single-stranded DNA probes using linear PCR; Application of the method for analysis of strand-specific DNA repair. Mutat. Res., 315: 189-195, 1994.
42. Denissenko, M. F., Venkatachalam, S., Ma, Y. H., and Wani, A. A. Site-specific induction and repair of benzo[a]pyrene diol epoxide DNA damage in human H-ras proto-oncogene as revealed by restriction cleavage inhibition. Mutat. Res., 363: 27-42, 1996.
43. Tainsky, M. A., Bischoff, F. Z., and Strong, L. C. Genomic instability due to germ-line p53 mutations drives preneoplastic progression toward cancer in human cells. Cancer Metastasis Rev., 14: 43-48, 1995.
44. Sancar, A. Mechanisms of DNA excision repair. Science (Washington DC), 266: 1954-1956, 1994.
45. Hanawalt, P., and Mellon, I. Stranded in an active gene. Curr. Biol., 3: 67-69, 1994.
46. El-Deiry, W. S. p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol., 227: 121-137, 1998.
47. Hall, P. A., McKee, P. H., Menage, H. P., Dover, R., and Lane, D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8: 203-207, 1993.
48. Zhan, Q., Carrier, F., and Fomace, A. J. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell Biol., 13: 4242-4250, 1993.
49. Smith, M. L., Chen, I. T., Zhan, Q., Bae, I., Chen, C-Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M., and Fornace, A. J., Jr. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (Washington DC), 266: 1376-1380, 1994.
50. Fan, S., Smith, M. L., Rivet, D. J., H. Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
51. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J-M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H. J., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10: 188-195, 1995.
52. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
53. Liu, M., and Pelling, J. C. UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression. Oncogene. 10: 1955-1960, 1995.
54. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Ievrero, M., and Wang, J. Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin induced DNA damage. Nature (Lond.), 399: 806-809, 1999.
55. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. p73 is a human p53-related protein that can induce apoptosis. Nature (Lond.). 389: 191-194, 1997.
56. Smith, M. L., Chen, I-T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene, 10: 1053-1059, 1995.
57. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of p53 tumor suppressor-DNA complex: understanding tumorigemc mutations. Science (Washington DC), 265: 346-355, 1994.
58. Milner, J., and Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives wild type p53 protein into the mutant conformation. Cell, 65: 765-774, 1991.
59. Srivastava, S., Wang, S., Tong, Y. A., Pirollo, K., and Chang, E. H. Several mutant protein detected in Li-Fraumenic syndrome exhibit transdominant effects on the biochemical properties of wild-type p53. Oncogene, 8: 2449-2456, 1993.
60. Sands, A. T., Suraokar, M. B., Sanchez, A., Marth, J. E., Donehower, L. A., and Bradley, A. p53 deficiency does not effect the accumulation of point mutations in transgene target. Proc. Natl. Acad. Sci. USA, 92: 8517-8521, 1995.
61. McGregor, W. G., Mah, M. C. M., Chen, R. H., Maher, V. M., and McCormick, J. J. Lack of correlation between degree of interference with transcription and rate of strand specific repair in the HPRT gene of diploid human fibroblasts. J. Biol. Chem., 270: 27222-27227, 1995.
62. Maher, V. M., Dorney, D. J., Konze-Thomas, B., and McCormick, J. DNA excision-repair processes in human cells can eliminate the cytotoxic and mutagenic consequences of ultraviolet irradiation. Mutat. Res., 62: 311-339, 1979.
63. Leadon, S. A. Transcription-coupled repair of DNA damage: Unanticipated players, unexpected complexities. Am. J. Hum. Genet., 64: 1259-1263, 1999.
64. Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B., and Stark, G. R. The p53 network. J. Biol. Chem., 273: 1-4, 1998.
65. Canman, C. E., Chen, C-Y., Lee, M-H., and Kastan, M. B. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harbor Symp. Quant. Biol., 59: 277-286, 1994.
66. Strasser, A., Harris, A. W., Jacks, T., and Cory, S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bc1-2. Cell. 79: 329-339, 1994.
67. Waf1/cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene, 18: 2789-2797, 1999.
68. Walker, P. R., Weaver, V. M., Lach, B., Leblanc, J., and Sikorska, M. Endonuclease activities associated with high molecular weight and internucleosomal DNA fragmentation in apoptosis. Exp. Cell Res., 213: 100-106, 1994.
69. Ford, J. M., Baron, E. L., and Hanawalt, P. C. Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res., 58: 599-603, 1998.
70. Zhan, Q. M., Antinore, M. J., Wang, X. W., Carrier, F., Smith, M. L., Harris, C. C., and Forance, A. J., Jr. Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene, 18: 2892-2900, 1999.